WAT

AI Memo

Waters

As of 2026-06-18/Confidence high/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-06-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

6‑12m

Key catalyst

Q1 beat-and-raise reset the FY26 bar higher • 2026-05-05

Expected move: +4%

Biggest risk

The bear case is that this remains an execution-monitoring story, not a clean rerating: Q2 adjusted EPS guidance of $2.95-$3.05 implies only flat to 3.4% year-over-year growth, GAAP profitability is still heavily burdened by acquisition accounting, and the 10-Q shows materially higher goodwill and debt after the deal, leaving less room for integration slippage [#SEC-8K-2026-05-05][#SEC-10Q-2026-05-12].

Invalidation

Break below $320 or thesis failure.

What would change my mind?

The bull case is that Q1 already showed the combined company can beat on both core Waters demand and the newly acquired BD assets: organic constant-currency growth was 11%, the acquired businesses delivered $520 million of owned-period revenue versus guidance that was $40 million lower, and management raised full-year revenue and EPS guidance while pointing to early revenue-synergy traction [#SEC-8K-2026-05-05].

Research note

Recommendation

—

Confidence

high

As of

2026-06-18

Base target

$395

p=50%

Bull target

$425

p=30%

Bear target

$320

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

BD biosciences and diagnostics integration is the main multi-quarter upside lever
Execution must outrun leverage, amortization, and China friction
The bull case is that Q1 already showed the combined company can beat on both core Waters demand and the newly acquired BD assets: organic constant-currency growth was 11%, the acquired businesses delivered $520 million of owned-period revenue versus guidance that was $40 million lower, and management raised full-year revenue and EPS guidance while pointing to early revenue-synergy traction [#SEC-8K-2026-05-05].

BearKey bullets

China demand, procurement restrictions, tariff uncertainty, and local competition remain explicit risks in company filings [#10-K-2026-02-23][#SEC-10Q-2026-05-12].
Higher leverage and acquisition-accounting drag: total debt was about $5.215 billion and goodwill about $9.317 billion as of April 4, 2026, increasing downside if growth slows [#SEC-10Q-2026-05-12].
Integration and synergy realization risk around the BD Biosciences and Diagnostic Solutions acquisition, including failure to achieve expected revenue and cost synergies [#SEC-10Q-2026-05-12].

WatchKey bullets

Q1 beat-and-raise reset the FY26 bar higher

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $395 (p=50%)

Bull/Bear spread: +12% / -15%

Vs latest close: Bull +12% · Base +4% · Bear -15%

Scenario probabilities

Bull Target: $425 (p=30%)Base Target: $395 (p=50%)Bear Target: $320 (p=20%)

Commentary

Primary-source evidence is strong and directionally positive, but the thesis change is still moderate rather than dramatic. The stock’s post-earnings tone appears constructive, consistent with the beat-and-raise, yet by the June 17, 2026 anchor much of that reset likely sits in the price already. News flow after the May 5 print is thin, social context is unavailable, and analyst-revision breadth is incomplete, so this remains a cautious execution-monitoring long rather than a fresh high-conviction rerating call.

As of 2026-06-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

BD biosciences and diagnostics integration is the main multi-quarter upside lever
Execution must outrun leverage, amortization, and China friction

Scenarios

Bull Target (Scenario probability)

$425 / p=30% prob

Base Target (Scenario probability)

$395 / p=50% prob

Bear Target (Scenario probability)

$320 / p=20% prob

Price $378 as of 2026-07-16

Nearest Scenario: Base (∆ 4%)

Targets vs latest close: Bull +12% · Base +4% · Bear -15%

Sentiment & Exposure

News Sentiment (30d)

66.00

Social Sentiment (7d)

50.00

Events

Other notable items detected

EVENT2026-05-05
Q1 beat-and-raise reset the FY26 bar higher
Waters reported Q1 2026 revenue of $1.267 billion, organic constant-currency growth of 11%, adjusted EPS of $2.70, and raised FY26 guidance to 6.5%-8.0% organic constant-currency growth and $14.40-$14.60 adjusted EPS; that moved the debate from whether the BD assets would dilute growth to whether Waters can sustain the higher bar [#SEC-8K-2026-05-05].
Prob 88.00% • Move 3.00% • Priced-in 82.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

BD biosciences and diagnostics integration is the main multi-quarter upside lever
2026-12-31
The acquired Biosciences and Diagnostic Solutions businesses contributed $520 million of owned-period Q1 revenue, $40 million above guidance, while Waters said revenue synergies were already showing and embedded $15 million of FY26 organic synergy and $35 million of acquired-business synergy into guidance; sustaining that momentum is central to further upside [#SEC-8K-2026-05-05].
Prob 67% • Move 7% • Priced-in 52%
Execution must outrun leverage, amortization, and China friction
2026-12-31
The 10-Q shows goodwill rising to about $9.3 billion after the acquisition and total debt at about $5.215 billion as of April 4, 2026, while the 10-K and 10-Q continue to flag China procurement, tariff, and competitive risks; that leaves the stock dependent on durable organic instruments/consumables/service demand rather than a one-quarter spike [#SEC-10Q-2026-05-12][#10-K-2026-02-23].
Prob 62% • Move 5% • Priced-in 57%

Risks

China demand, procurement restrictions, tariff uncertainty, and local competition remain explicit risks in company filings [#10-K-2026-02-23][#SEC-10Q-2026-05-12].
Higher leverage and acquisition-accounting drag: total debt was about $5.215 billion and goodwill about $9.317 billion as of April 4, 2026, increasing downside if growth slows [#SEC-10Q-2026-05-12].
Integration and synergy realization risk around the BD Biosciences and Diagnostic Solutions acquisition, including failure to achieve expected revenue and cost synergies [#SEC-10Q-2026-05-12].
Q2 guidance calls for only flat to modest adjusted EPS growth year over year despite the Q1 beat, so near-term expectations are not trivial to clear [#SEC-8K-2026-05-05].

Peers

Symbol	Summary
A	Agilent is the cleanest direct peer because Waters names Agilent among principal competitors in service, core analytical instruments, and consumables markets [#10-K-2026-02-23].
BRKR	Bruker is a relevant analytical-instruments comparator because Waters lists Bruker among principal competitors in the markets served by Waters, making it useful for mass-spec and instrument-cycle read-throughs [#10-K-2026-02-23].
TMO	Thermo Fisher is a direct large-cap peer for instruments, consumables, and service because Waters cites Thermo Fisher as a principal competitor across those markets [#10-K-2026-02-23].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-06-18

AI Stock Memo: WAT - Waters - RankAlpha